AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23085971 — intervention group
Group type: COMPARATOR
Intervention: 10,000 kg load-volume
Number of subjects: 8
Study 21303566 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep TMS applied for 10 min (600 pulses per session) to the left temporoparietal cortex for either 10 or 20 sessions.
Number of subjects: 8
Study 19736899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (5 microg) plus intrathecal morphine (150 microg)
Number of subjects: 64
Study 19736899 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal sufentanil (5 microg) plus single administration of 10 mg subcutaneous morphine
Number of subjects: 64
Study 17163810 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Number of subjects: 0
Study 17163810 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan with concomitant warfarin
Number of subjects: 0
Study 15068753 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored nutrition education CD-ROM program
Number of subjects: 307
Study 15068753 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 307
Study 11402112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral white matter lesions (WML) severity
Number of subjects: 1049
Study 11402112 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe WML
Number of subjects: 1049
Study 11402112 — intervention group
Group type: EXPERIMENTAL
Intervention: Periventricular WML
Number of subjects: 1049
Study 11402112 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcortical WML
Number of subjects: 1049
Study 9640068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic skin response examination in patients with MS
Number of subjects: 24
Study 9640068 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability tests in patients with MS
Number of subjects: 24
Study 9640068 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure response to standing in patients with MS
Number of subjects: 24
Study 9640068 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination in patients with MS
Number of subjects: 24
Study 9640068 — intervention group
Group type: COMPARATOR
Intervention: Sympathetic skin response examination in controls
Number of subjects: 24
Study 7958673 — intervention group
Group type: EXPERIMENTAL
Intervention: High transcutaneous electrical nerve stimulation (100 Hz, 100 microseconds)
Number of subjects: 8
Study 7958673 — intervention group
Group type: COMPARATOR
Intervention: No somatic stimulation (control)
Number of subjects: 8
Study 2521722 — intervention group
Group type: EXPERIMENTAL
Intervention: Opium (10(30) dilution, 15 HC)
Number of subjects: 600
Study 2521722 — intervention group
Group type: EXPERIMENTAL
Intervention: Raphanus (10(10) dilution, 5 HC)
Number of subjects: 600
Study 2521722 — intervention group
Group type: EXPERIMENTAL
Intervention: Opium and placebo of Raphanus
Number of subjects: 600
Study 2521722 — intervention group
Group type: COMPARATOR
Intervention: Placebos of both products
Number of subjects: 600
Study 52854 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (60 mg per day) and Quinidine (0.60 g per day)
Number of subjects: 184
Study 52854 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (0.80 g per day)
Number of subjects: 184
Study 30676622 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study
Number of subjects: 125
Study 30676622 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 125
Study 29975403 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking exercise
Number of subjects: 213
Study 29975403 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise
Number of subjects: 213
Study 29975403 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 213
Study 26729394 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and early electrical stimulation (ES) to the wrist flexors and extensors for 30 min twice a day, 5 days a week for 3 months
Number of subjects: 40
Study 26729394 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 24375295 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-Fr pigtail catheter
Number of subjects: 40
Study 24375295 — intervention group
Group type: COMPARATOR
Intervention: 28-Fr chest tube
Number of subjects: 40
Study 22151064 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg · kg(‐1) GHB
Number of subjects: 36
Study 22151064 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg · kg(‐1) GHB
Number of subjects: 36
Study 22151064 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg · kg(‐1) GHB
Number of subjects: 36
Study 20619853 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (10 or 20 mg/day depending on age) for 10 days
Number of subjects: 141
Study 20619853 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 141
Study 17195697 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib-MenC coadministered with DTPa-HBV-IPV
Number of subjects: 237
Study 17195697 — intervention group
Group type: COMPARATOR
Intervention: MenC-CRM coadministered with DTPa-HBV-IPV/Hib
Number of subjects: 237
Study 15726891 — intervention group
Group type: EXPERIMENTAL
Intervention: High-AGE (AGE 2.4 ml/day)
Number of subjects: 51
Study 15726891 — intervention group
Group type: COMPARATOR
Intervention: Low-AGE (AGE 0.16 ml/day)
Number of subjects: 51
Study 12240812 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored hospital intervention (workshops, policy review, multidisciplinary meetings, rounds, unit discussions)
Number of subjects: 200
Study 12240812 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored hospital intervention
Number of subjects: 200
Study 12240812 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tailored intervention)
Number of subjects: 200
Study 9853997 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryo/Cuff (group 1)
Number of subjects: 30
Study 9853997 — intervention group
Group type: COMPARATOR
Intervention: Wound dressing (group 2)
Number of subjects: 30
Study 8136443 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education (intervention group)
Number of subjects: 160
Study 8136443 — intervention group
Group type: COMPARATOR
Intervention: Individual education (control group)
Number of subjects: 160
Study 2813561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 8
Study 2813561 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 8
Study 1175910 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric acupuncture
Number of subjects: 15
Study 1175910 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 15
Study 1175910 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 15
Study 31174215 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN (without iron)
Number of subjects: 760
Study 31174215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe + MMN
Number of subjects: 760
Study 31174215 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe (60 mg)
Number of subjects: 760
Study 31174215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760
Study 27798075 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of mephedrone administered orally
Number of subjects: 6
Study 26354530 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest Dietary Inflammatory Index (DII) score (anti-inflammatory diet)
Number of subjects: 520
Study 26354530 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in DII (greater anti-inflammatory potential of the diet)
Number of subjects: 520
Study 26354530 — intervention group
Group type: COMPARATOR
Intervention: Highest DII tertile (pro-inflammatory diet)
Number of subjects: 520
Study 26354530 — intervention group
Group type: COMPARATOR
Intervention: Greatest pro-inflammatory values after 5-year follow-up
Number of subjects: 520
Study 24228535 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune 2 plus HAART
Number of subjects: 264
Study 24228535 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus HAART
Number of subjects: 264
Study 21843835 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised foot orthoses
Number of subjects: 400
Study 21843835 — intervention group
Group type: COMPARATOR
Intervention: No shoe insert or orthosis (Control)
Number of subjects: 400
Study 17574300 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire on Craving for Sweet or Rich Foods (QCSRF)
Number of subjects: 385
Study 17574300 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor 1 (six items assessing perceptions about sweet or rich foods)
Number of subjects: 385
Study 17574300 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor 2 (three items assessing intensity of cravings)
Number of subjects: 385
Study 16922941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL) therapy following 30% Salicylic Acid (SA) application twice a day for 5 days
Number of subjects: 19
Study 16922941 — intervention group
Group type: COMPARATOR
Intervention: Pulsed Dye Laser (PDL) therapy alone
Number of subjects: 19
Study 12712081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment for three cycles followed by placebo for one cycle
Number of subjects: 0
Study 12712081 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for three cycles followed by placebo for one cycle
Number of subjects: 0
Study 11085959 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating immune complexes (CICs)
Number of subjects: 257
Study 11085959 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibodies to cardiolipin
Number of subjects: 257
Study 11085959 — intervention group
Group type: EXPERIMENTAL
Intervention: C4 null alleles
Number of subjects: 257
Study 11085959 — intervention group
Group type: EXPERIMENTAL
Intervention: CICs and autoantibodies against cardiolipin
Number of subjects: 257
Study 8638014 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral CT with pitch 1.2
Number of subjects: 109
Study 8638014 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral CT with pitch 1.5
Number of subjects: 109
Study 8638014 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral CT with pitch 2.0
Number of subjects: 109
Study 8638014 — intervention group
Group type: COMPARATOR
Intervention: Spiral CT with standard pitch (1.0)
Number of subjects: 109
Study 8500859 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril monotherapy or combined with hydrochlorothiazide
Number of subjects: 74
Study 8500859 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (metoprolol, hydrochlorothiazide, or both)
Number of subjects: 74
Study 8500859 — intervention group
Group type: COMPARATOR
Intervention: Captopril or conventional therapy
Number of subjects: 74
Study 29396092 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (750 μg subcutaneously once per week for 58 weeks)
Number of subjects: 250
Study 29396092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 24296848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 5518
Study 24296848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5518
Study 24296848 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate and TZD
Number of subjects: 5518
Study 24296848 — intervention group
Group type: COMPARATOR
Intervention: Neither fenofibrate nor TZD
Number of subjects: 5518
Study 22482610 — intervention group
Group type: EXPERIMENTAL
Intervention: Curvilinear approach for prostate seed implantation
Number of subjects: 20
Study 19672050 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuttle Walking Test (SWT)
Number of subjects: 50
Study 18593491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Support Ventilation (PSV)
Number of subjects: 14
Study 18593491 — intervention group
Group type: COMPARATOR
Intervention: Volume Controlled-Continuous Mandatory Ventilation (VC-CMV)
Number of subjects: 14
Study 18593491 — intervention group
Group type: COMPARATOR
Intervention: Pressure-Regulated Volume-Control Ventilation (PRVC)
Number of subjects: 14
Study 15809384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group taught a system using heart sounds as an internal reference
Number of subjects: 100
Study 15809384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 100
Study 11920549 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized uncertainty management intervention delivered by telephone (weekly phone calls for 8 weeks)
Number of subjects: 239
Study 11920549 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 239
Study 10507379 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 404
Study 10507379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 7557711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 2
Study 2113376 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course (SC) of systemic antibiotics
Number of subjects: 203
Study 2113376 — intervention group
Group type: COMPARATOR
Intervention: Long course (LC) of systemic antibiotics
Number of subjects: 203
Study 391657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg on entering the study followed by 400 mg six hourly)
Number of subjects: 101
Study 391657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 31348053 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation group (n = 37)
Number of subjects: 73
Study 31348053 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 36)
Number of subjects: 73
Study 31614295 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training for 8 weeks, 7 days per week, twice daily
Number of subjects: 47
Study 27149590 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 42
Study 27149590 — intervention group
Group type: COMPARATOR
Intervention: Placebo Kinesio Tape (KT)
Number of subjects: 42
Study 26052875 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + I/EP
Number of subjects: 83
Study 26052875 — intervention group
Group type: COMPARATOR
Intervention: CBT + SL
Number of subjects: 83
Study 23535796 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic cycling training (12 weeks, 5 times/week)
Number of subjects: 128
Study 23535796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 128
Study 21487251 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir, lamivudine and nevirapine or efavirenz; children in induction-maintenance arms also received zidovudine to week 36; Pre-ART inpatient/outpatient nutritional rehabilitation for children with baseline severe malnutrition
Number of subjects: 1207
Study 19398166 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine replacement therapy
Number of subjects: 0
Study 16926171 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention program
Number of subjects: 82
Study 16926171 — intervention group
Group type: COMPARATOR
Intervention: Coping intervention program
Number of subjects: 82
Study 16926171 — intervention group
Group type: COMPARATOR
Intervention: Combination program
Number of subjects: 82
Study 14960294 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (.1 mg/day)
Number of subjects: 57
Study 14960294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 14960294 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estradiol-medroxyprogesterone
Number of subjects: 57
Study 11502805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone and prednisone treatment
Number of subjects: 26
Study 9258849 — intervention group
Group type: EXPERIMENTAL
Intervention: Weights group performing heavy squats
Number of subjects: 0
Study 9258849 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 7953934 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive oral health care programme
Number of subjects: 212
Study 7953934 — intervention group
Group type: COMPARATOR
Intervention: Non-participating control group
Number of subjects: 212
Study 2885080 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin and bleomycin) followed by standard therapy (surgery and postoperative radiotherapy)
Number of subjects: 462
Study 2885080 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy and standard therapy followed by maintenance chemotherapy (six cycles of monthly cisplatin)
Number of subjects: 462
Study 2885080 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 462
Study 29884456 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (15 mg)
Number of subjects: 23
Study 29884456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 27514628 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 3887
Study 27514628 — intervention group
Group type: COMPARATOR
Intervention: Routine Medical Therapy (RMT)
Number of subjects: 3887
Study 25394549 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage (15 minutes, 2 times daily for 5 days)
Number of subjects: 27
Study 25394549 — intervention group
Group type: COMPARATOR
Intervention: Control group (no abdominal massage)
Number of subjects: 27
Study 23423270 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC-MMF
Number of subjects: 60
Study 23423270 — intervention group
Group type: COMPARATOR
Intervention: CsA-MMF
Number of subjects: 60
Study 19444295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery (expedited, approximately 4 weeks)
Number of subjects: 239
Study 19444295 — intervention group
Group type: COMPARATOR
Intervention: Control (routine surgery, 12 months wait)
Number of subjects: 239
Study 18834367 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbekacin (ABK)
Number of subjects: 10
Study 18834367 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 10
Study 16624687 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone case management (6 months)
Number of subjects: 134
Study 16624687 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study 12730478 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplementation
Number of subjects: 0
Study 12730478 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 12730478 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 0
Study 12730478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition interventions
Number of subjects: 0
Study 12730478 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal interventions
Number of subjects: 0
Study 11061773 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine inhalation
Number of subjects: 19
Study 11061773 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 19
Study 8861677 — intervention group
Group type: EXPERIMENTAL
Intervention: N diet and NaHCO(3) ingestion
Number of subjects: 6
Study 8861677 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-CHO diet and NaHCO(3) ingestion
Number of subjects: 6
Study 8861677 — intervention group
Group type: COMPARATOR
Intervention: Low-CHO diet
Number of subjects: 6
Study 8861677 — intervention group
Group type: COMPARATOR
Intervention: N diet and placebo
Number of subjects: 6
Study 8861677 — intervention group
Group type: COMPARATOR
Intervention: Low-CHO diet and placebo
Number of subjects: 6
Study 1739360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 140
Study 6135439 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg (i.v.) doxazosin
Number of subjects: 6
Study 6135439 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg (oral) doxazosin
Number of subjects: 6
Study 6135439 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (both routes)
Number of subjects: 6
Study 6135439 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin concentration
Number of subjects: 6
Study 31337171 — intervention group
Group type: EXPERIMENTAL
Intervention: AAJ injection with 1.0 mL of a mixture of 0.5 mL of bupivacaine 0.5% and 0.5 mL of 20 mg of triamcinolone, plus oral placebo tablets (2 tablets every 8 hours for one week)
Number of subjects: 60
Study 31337171 — intervention group
Group type: COMPARATOR
Intervention: Systemic steroids, oral prednisolone tablets (5 mg, 2 tablets every 8 hours for one week), plus AAJ injection with 1.0 mL of a mixture of 0.5 mL of bupivacaine 0.5% and 0.5 mL of normal saline solution
Number of subjects: 60
Study 29386173 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored cognitive behavioral therapy (CancerCope)
Number of subjects: 163
Study 29386173 — intervention group
Group type: COMPARATOR
Intervention: Static patient education website
Number of subjects: 163
Study 27028912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17β‐estradiol (1 mg per day, plus progesterone [45 mg] vaginal gel administered sequentially for women with a uterus)
Number of subjects: 643
Study 27028912 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plus sequential placebo vaginal gel for women with a uterus)
Number of subjects: 643
Study 27028912 — intervention group
Group type: COMPARATOR
Intervention: Oral 17β‐estradiol and Placebo
Number of subjects: 643
Study 25197990 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (G1)
Number of subjects: 45
Study 25197990 — intervention group
Group type: COMPARATOR
Intervention: Inert wax material (G2)
Number of subjects: 45
Study 22824593 — intervention group
Group type: COMPARATOR
Intervention: Grid laser treatment alone
Number of subjects: 30
Study 22824593 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of intravitreal injection of ranibizumab (0.5 mg / 0.05 ml) followed by grid laser treatment on 7th day
Number of subjects: 30
Study 22824593 — intervention group
Group type: EXPERIMENTAL
Intervention: Three loading doses of intravitreal ranibizumab at monthly intervals + standard laser treatment 7 days after the 1st injection
Number of subjects: 30
Study 20650668 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of calf muscles at rates of 2 to 120 bpm
Number of subjects: 24